2025
Household transmission of SARS-CoV-2 in five US jurisdictions: Comparison of Delta and Omicron variants
Baker J, Nakayama J, O’Hegarty M, McGowan A, Teran R, Bart S, Sosa L, Brockmeyer J, English K, Mosack K, Bhattacharyya S, Khubbar M, Yerkes N, Campos B, Paegle A, McGee J, Herrera R, Pearlowitz M, Williams T, Kirking H, Tate J. Household transmission of SARS-CoV-2 in five US jurisdictions: Comparison of Delta and Omicron variants. PLOS ONE 2025, 20: e0313680. PMID: 39787187, PMCID: PMC11717262, DOI: 10.1371/journal.pone.0313680.Peer-Reviewed Original ResearchConceptsPublic health jurisdictionsTransmission riskGeneralized estimating equationsHealth jurisdictionsSARS-CoV-2 transmissionSARS-CoV-2Household contactsIndex casePrevention strategiesRisk estimatesImpact SARS-CoV-2 transmissionConfidence intervalsSymptom statusMultivariate modelUS jurisdictionsSARS-CoV-2 DeltaEstimate differencesHousehold transmission rateOmicron variantSocial factorsSource of SARS-CoV-2 transmissionCOVID-19 vaccine dosesSARS-CoV-2 variantsRiskSymptomatic index cases
2024
A predictive language model for SARS-CoV-2 evolution
Ma E, Guo X, Hu M, Wang P, Wang X, Wei C, Cheng G. A predictive language model for SARS-CoV-2 evolution. Signal Transduction And Targeted Therapy 2024, 9: 353. PMID: 39710752, PMCID: PMC11663983, DOI: 10.1038/s41392-024-02066-x.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 evolutionHot mutation spotsFrequency of mutationsSequence dataS1 sequencesVital mutationsPredicted mutationsSARS-CoV-2 variantsMutationsViral evolutionSARS-CoV-2Viral pathogensMutation profilesVariantsImmune evasionSequenceMutation spotsPredictive language modelViral mutationsLanguage modelStrainViral infectionSemantic representationMachine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines
Kovalchik K, Hamelin D, Kubiniok P, Bourdin B, Mostefai F, Poujol R, Paré B, Simpson S, Sidney J, Bonneil É, Courcelles M, Saini S, Shahbazy M, Kapoor S, Rajesh V, Weitzen M, Grenier J, Gharsallaoui B, Maréchal L, Wu Z, Savoie C, Sette A, Thibault P, Sirois I, Smith M, Decaluwe H, Hussin J, Lavallée-Adam M, Caron E. Machine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines. Nature Communications 2024, 15: 10316. PMID: 39609459, PMCID: PMC11604954, DOI: 10.1038/s41467-024-54734-9.Peer-Reviewed Original ResearchConceptsT cell epitopesT cellsCD8+ T cell epitopesT cell immunityT cell epitope discoverySARS-CoV-2T-cell-directed vaccinationDesigning effective vaccinesB7 supertypePatient's proteomesSARS-CoV-2 variantsVaccine epitopesViral antigensSpike antigenVaccine developmentEffective vaccineEpitope discoveryCOVID-19 vaccineVaccineEpitopesAntigenic featuresOmicron variantAntigenCOVID-19CD8No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota
Parry R, Lytras S, Petrone M, Wille M, Crits-Christoph A, Gifford R, Saito A, Smura T, Peacock T. No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota. Journal Of Virology 2024, 98: e01468-24. PMID: 39494907, PMCID: PMC11650967, DOI: 10.1128/jvi.01468-24.Peer-Reviewed Original ResearchBacterial sequencesViral RNA-dependent RNA polymeraseRNA-dependent RNA polymeraseSARS-CoV-2 variantsBacterial protein sequencesSARS-CoV-2 proteinsEvolution of mutationsRNA polymeraseIntrahost diversityProtein sequencesHomologous fragmentsNucleotide sequenceProtein databaseTemplate-switchingGut microbiotaSARS-CoV-2 VOCsViral genomeSARS-CoV-2Mutated fragmentsAmino acidsRdRpMutationsSequenceViral replicationProteinSpatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants
Zhang J, Xu Y, Chen M, Wang S, Lin G, Huang Y, Yang C, Yang Y, Song Y. Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants. Angewandte Chemie International Edition 2024, 63: e202412294. PMID: 39030890, DOI: 10.1002/anie.202412294.Peer-Reviewed Original ResearchNanoparticle vaccineReceptor-binding domainHeterotypic antigensBroad-spectrum neutralizing antibodiesSARS-CoV-2 spike trimerVaccine-induced immunityNanotechnology-based strategiesEnhanced immune activationOmicron receptor-binding domainMosaic vaccinesImmune activationSystematic in vitroNeutralizing antibodiesSARS-CoV-2 variantsMosaic nanoparticlesImmunological investigationsExcessive inflammationAntigen distributionAntigenSpike trimerRBD antigenSARS-CoV-2DNAVaccineAntiviral capabilitiesSpatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants
Zhang J, Xu Y, Chen M, Wang S, Lin G, Huang Y, Yang C, Yang Y, Song Y. Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants. Angewandte Chemie 2024, 136 DOI: 10.1002/ange.202412294.Peer-Reviewed Original ResearchNanoparticle vaccineReceptor-binding domainHeterotypic antigensBroad-spectrum neutralizing antibodiesSARS-CoV-2 spike trimerVaccine-induced immunityNanotechnology-based strategiesEnhanced immune activationOmicron receptor-binding domainMosaic vaccinesImmune activationSystematic in vitroNeutralizing antibodiesSARS-CoV-2 variantsMosaic nanoparticlesImmunological investigationsExcessive inflammationAntigen distributionAntigenSpike trimerRBD antigenSARS-CoV-2DNAVaccineAntiviral capabilitiesImmunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: a prospective observational study in Vietnam
Thanh T, Tu N, Nguyet L, Thuy C, Thuan N, Ny N, Nhu L, Thanh L, Hong N, Anh N, Truong N, Van Vinh Chau N, Yen L, Van E P, Thuong N, Van Truc N, Trung P, Yap W, Pandey R, Yee S, Weng R, Mongkolsapaya J, Dejnirattisai W, Hamers R, Chantratita N, Screaton G, Dunachie S, Jones E, Stuart D, Dung N, Thwaites G, Wang L, Tan C, Van Tan L, Wang L, Cruz K, Yee S, Lu H, Ruifen W, Pandey R, Young B, Sundar R, Soebandrio A, Sawitri A, Sutarsa I, Chan Y, Jantarabenjakul W, Chan N, Tan C, Van Tan L, Anh N, Hong N, Truc T, Ny N, Han D, Thanh L, Nguyet L, Thuy C, Nhu L, Thanh T, Yen L, Hang V, Kieu P, Hoang V, Thao N, Chambers M, Thanh V, Hoang T, van Doorn H, Tung T, Thwaites C, Thwaites G, Wang L, Lim B, Hamers R, Shankar A, Suwarti S, Tayipto Y, Simarmata E, Dien R, Mongkolsapaya J, Dejnirattisai W, Chantima W, Chantratita N, Poolchanuan P, Tiacharoen V, Dulsuk A, Iamsirithaworn S, Day N, Cheah P, Poomchaichote T, Boonthaworn K, Screaton G, Dijokaite-Guraliuc A, Das R, Liu C, Supasa P, Selvaraj M, Dunachie S, Klenerman P, Jones E, Stuart D, Kronsteiner-Dobramysl B, Zewdie M, Abraham P, Hill J, Ngoc N, Grifoni A, Sette A, Yap W, Tan C, Van Tan L. Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: a prospective observational study in Vietnam. International Journal Of Infectious Diseases 2024, 147: 107173. PMID: 39094762, DOI: 10.1016/j.ijid.2024.107173.Peer-Reviewed Original ResearchSARS-CoV-2 variantsSARS-CoV-2Neutralizing antibodiesBooster doseCOVID-19 vaccineCross-neutralizationAntibody responseMeasured anti-nucleocapsidVietnamese healthcare workersBooster vaccinationSARS-CoV-1Ancestral SARS-CoV-2Anti-spike antibodiesProspective observational studyCross-neutralizing activityProtein subunit vaccinesEnhanced antibody responseNeutralizing antibody titersMRNA BNT162b2ChAdOx1 vaccineAnti-spikeAnti-nucleocapsidPrimary vaccinationCollected blood samplesObservational studyTherapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang Y, Li F, Du L. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses. Journal Of Nanobiotechnology 2024, 22: 304. PMID: 38822339, PMCID: PMC11140877, DOI: 10.1186/s12951-024-02573-7.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCoronavirus InfectionsCOVID-19HumansMiddle East Respiratory Syndrome CoronavirusPandemicsPneumonia, ViralSARS-CoV-2Severe acute respiratory syndrome-related coronavirusSingle-Domain AntibodiesSpike Glycoprotein, CoronavirusVirus InternalizationConceptsReceptor-binding domainPathogenic human CoVsHeavy-chain antibodiesSARS-CoV-2Development of nanobiotechnologiesPathogenic human coronavirusesSingle-domain antibodiesSARS-CoV-2 variantsS proteinViral entry processHuman CoVsViral spikeReemerging pathogensEvaluation of therapeutic agentsSARS-CoVVirus pathogenesisVariable domainsNanobodiesViral structuresPandemic potentialMERS-CoVPathogenic coronavirusesViral entryBinding affinityHuman coronavirusesSPIKENET: An Evidence-Based Therapy for Long COVID
Elumalai N, Hussain H, Sampath N, Shamaladevi N, Hajjar R, Druyan B, Rashed A, Ramamoorthy R, Kenyon N, Jayakumar A, Paidas M. SPIKENET: An Evidence-Based Therapy for Long COVID. Viruses 2024, 16: 838. PMID: 38932130, PMCID: PMC11209161, DOI: 10.3390/v16060838.Peer-Reviewed Original ResearchCarcinoembryonic antigen-related cell adhesion molecule 1Murine hepatitis virus-1Post-acute sequelae of COVID-19SARS-CoV-2 variantsSARS-CoV-2Development of severe inflammationCell adhesion molecule 1Long-term complicationsAdhesion molecule 1Multiple organ damagePotential therapeutic benefitMultiple SARS-CoV-2 variantsEvidence-based therapiesSequelae of COVID-19ACE2 receptor-binding domainSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Severe inflammationTissue edemaOrgan damageRespiratory syndrome coronavirus 2Long COVIDMolecule 1Receptor-binding domainSyndrome coronavirus 2Predicting clinical outcomes of SARS-CoV-2 infection during the Omicron wave using machine learning
Cogill S, Nallamshetty S, Fullenkamp N, Heberer K, Lynch J, Lee K, Aslan M, Shih M, Lee J. Predicting clinical outcomes of SARS-CoV-2 infection during the Omicron wave using machine learning. PLOS ONE 2024, 19: e0290221. PMID: 38662748, PMCID: PMC11045098, DOI: 10.1371/journal.pone.0290221.Peer-Reviewed Original ResearchConceptsHigh-risk groupSARS-CoV-2 infectionAnticoagulant useAdverse outcomesPredictor of adverse outcomesHigher risk of adverse outcomesLower body mass indexRisk of adverse outcomesVaccination of high-risk groupsOral anticoagulant useOutcome of SARS-CoV-2 infectionRetrospective longitudinal observational studySARS-CoV-2U.S. Veterans Health AdministrationClinical outcomes of SARS-CoV-2 infectionIdentification of patientsBody mass indexVeterans Health AdministrationPredictors of hospitalizationEscalation of careLongitudinal observational studyClinical outcomesOmicron SARS-CoV-2 variantSARS-CoV-2 variantsUnvaccinated patientsEvaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
Wells C, Pandey A, Moghadas S, Fitzpatrick M, Singer B, Galvani A. Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States. Annals Of Internal Medicine 2024, 177: 609-617. PMID: 38527289, DOI: 10.7326/m23-2451.Peer-Reviewed Original ResearchSARS-CoV-2 vaccination campaignSARS-CoV-2Centers for Disease Control and PreventionDisease Control and PreventionSARS-CoV-2 vaccinesHealth care costsVaccine-acquired immunityFood and Drug AdministrationU.S. Food and Drug AdministrationControl and PreventionNational Institutes of HealthVaccination campaignInfluenza vaccineInitial doseInstitutes of HealthSARS-CoV-2 variantsBooster doseImmune evasionDrug AdministrationUnited StatesNotsew Orm Sands FoundationDoseHealthPopulation immunityNational InstituteComparison of factors associated with seasonal influenza and COVID-19 booster vaccination coverage among healthcare personnel working at acute care hospitals during 2021–2022 influenza season, National Healthcare Safety Network, United States
Meng L, Bell J, Soe M, Edwards J, Lymon H, Barbre K, Reses H, Patel A, Wong E, Dudeck M, Huynh C, Rowe T, Dubendris H, Benin A. Comparison of factors associated with seasonal influenza and COVID-19 booster vaccination coverage among healthcare personnel working at acute care hospitals during 2021–2022 influenza season, National Healthcare Safety Network, United States. Preventive Medicine 2024, 179: 107852. PMID: 38211802, DOI: 10.1016/j.ypmed.2024.107852.Peer-Reviewed Original ResearchNational Healthcare Safety NetworkAcute care hospitalsInfluenza seasonCare hospitalHealthcare personnelInfluenza coverageFuture influenza seasonsSeasonal influenza vaccineSeasonal influenza virusesSARS-CoV-2 variantsUptake of vaccinationFacility-level factorsInfluenza vaccineVaccination coverageSeasonal influenzaVaccination dataHospitalInfluenza virusFacility characteristicsSafety NetworkSimultaneous circulationHealthcare facilitiesComparison of factorsCOVID-19Negative binomial mixed models
2023
Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations
Akhtar M, Islam M, Khaton F, Soltana U, Jafrin S, Rahman S, Tauheed I, Ahmed T, Khan I, Akter A, Khan Z, Islam M, Khanam F, Biswas P, Ahmmed F, Ahmed S, Rashid M, Hossain M, Alam A, Alamgir A, Rahman M, Ryan E, Harris J, LaRocque R, Flora M, Chowdhury F, Khan A, Banu S, Shirin T, Bhuiyan T, Qadri F. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Frontiers In Immunology 2023, 14: 1309997. PMID: 38173725, PMCID: PMC10763240, DOI: 10.3389/fimmu.2023.1309997.Peer-Reviewed Original ResearchConceptsFuture vaccination strategiesIgG responsesVaccination strategiesVaccine typesImmunological toleranceImmune responseMRNA dosesSpecific IgG antibody responseIgG subclass analysisRobust IgG responseChAdOx1 nCoV-19IgG antibody responsePrimary IgG responseSARS-CoV-2 variantsHumoral immune responseMRNA vaccine dosesCOVID-19 vaccinationNumber of dosesSARS-CoV-2 spike receptorBooster dosesBooster vaccinationIgG4 levelsIgG4 responsesMRNA vaccinationIgG levelsDifferences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53
Lee J, Menasche B, Mavrikaki M, Uyemura M, Hong S, Kozlova N, Wei J, Alfajaro M, Filler R, Müller A, Saxena T, Posey R, Cheung P, Muranen T, Heng Y, Paulo J, Wilen C, Slack F. Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53. Cell Reports 2023, 42: 113478. PMID: 37991919, PMCID: PMC10785701, DOI: 10.1016/j.celrep.2023.113478.Peer-Reviewed Original ResearchConceptsChromatin accessibilityProteomic compositionCellular senescenceTP53 stabilizationSARS-CoV-2 spikeCell-cell fusionPathogenic coronavirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsSenescence-associated inflammationSARS-CoV-2 infectionMiddle East respiratory syndromeAccessibility stateInflammatory cytokine releaseSevere respiratory infectionsSARS-CoV-2 variantsSignificant public health threatCoronavirus disease 2019SARS-CoV-2Public health threatBreakthrough infectionsRespiratory infectionsCytokine releaseSenescenceDisease 2019Respiratory syndromeGenomic characterization of SARS-CoV-2 from an indigenous reserve in Mato Grosso do Sul, Brazil
de Oliveira L, de Rezende I, Navarini V, Marchioro S, Torres A, Croda J, Croda M, Gonçalves C, Xavier J, de Castro E, Lima M, Iani F, Adelino T, Aburjaile F, Demarchi L, Taira D, Zardin M, Fonseca V, Giovanetti M, Andrews J, Alcantara L, Simionatto S. Genomic characterization of SARS-CoV-2 from an indigenous reserve in Mato Grosso do Sul, Brazil. Frontiers In Public Health 2023, 11: 1195779. PMID: 37965526, PMCID: PMC10641392, DOI: 10.3389/fpubh.2023.1195779.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 lineagesIntroduction eventsCharacterization of SARS-CoV-2Nanopore sequencing platformSARS-CoV-2 positive samplesMultiple SARS-CoV-2 variantsMultiple introduction eventsPhylogenetic reconstructionPhylogenetic dataGenome sequenceSequencing platformsGenomic characterizationSARS-CoV-2Genomic surveillanceSARS-CoV-2 variantsLineagesMato GrossoMortality rateViral dynamicsIndigenous populationCo-circulationPrevalence of malesMidwestern BrazilPositive samplesIndigenous mobilizationImmunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine
Grandi A, Tomasi M, Ullah I, Bertelli C, Vanzo T, Accordini S, Gagliardi A, Zanella I, Benedet M, Corbellari R, Di Lascio G, Tamburini S, Caproni E, Croia L, Ravà M, Fumagalli V, Di Lucia P, Marotta D, Sala E, Iannacone M, Kumar P, Mothes W, Uchil P, Cherepanov P, Bolognesi M, Pizzato M, Grandi G. Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine. Vaccines 2023, 11: 1546. PMID: 37896949, PMCID: PMC10610814, DOI: 10.3390/vaccines11101546.Peer-Reviewed Original ResearchSARS-CoV-2 vaccinesSARS-CoV-2Outer membrane vesiclesImmune responseSARS-CoV-2 elicitsSARS-CoV-2 variantsPotent immune responsesEffective immune responsePre-clinical efficacyDiverse SARS-CoV-2 variantsInherent adjuvanticityVaccinated miceIntranasal challengeVaccine dosesNeutralization titresEffective vaccineVirus infectionVaccination campaignHeterologous antigensVaccineVirus replicationSpike proteinInfectivity assaysTitresPotential needClinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium
Sperotto F, Gutiérrez-Sacristán A, Makwana S, Li X, Rofeberg V, Cai T, Bourgeois F, Omenn G, Hanauer D, Sáez C, Bonzel C, Bucholz E, Dionne A, Elias M, García-Barrio N, González T, Issitt R, Kernan K, Laird-Gion J, Maidlow S, Mandl K, Ahooyi T, Moraleda C, Morris M, Moshal K, Pedrera-Jiménez M, Shah M, South A, Spiridou A, Taylor D, Verdy G, Visweswaran S, Wang X, Xia Z, Zachariasse J, EHR T, Aaron J, Adam A, Agapito G, Albayrak A, Albi G, Alessiani M, Alloni A, Amendola D, Angoulvant F, Anthony L, Aronow B, Ashraf F, Atz A, Avillach P, Panickan V, Azevedo P, Badenes R, Balshi J, Batugo A, Beaulieu-Jones B, Beaulieu-Jones B, Bell D, Bellasi A, Bellazzi R, Benoit V, Beraghi M, Bernal-Sobrino J, Bernaux M, Bey R, Bhatnagar S, Blanco-Martínez A, Boeker M, Bonzel C, Booth J, Bosari S, Bourgeois F, Bradford R, Brat G, Bréant S, Brown N, Bruno R, Bryant W, Bucalo M, Bucholz E, Burgun A, Cai T, Cannataro M, Carmona A, Cattelan A, Caucheteux C, Champ J, Chen J, Chen K, Chiovato L, Chiudinelli L, Cho K, Cimino J, Colicchio T, Cormont S, Cossin S, Craig J, Cruz-Bermúdez J, Cruz-Rojo J, Dagliati A, Daniar M, Daniel C, Das P, Devkota B, Dionne A, Duan R, Dubiel J, DuVall S, Esteve L, Estiri H, Fan S, Follett R, Ganslandt T, García-Barrio N, Garmire L, Gehlenborg N, Getzen E, Geva A, Goh R, González T, Gradinger T, Gramfort A, Griffier R, Griffon N, Grisel O, Gutiérrez-Sacristán A, Guzzi P, Han L, Hanauer D, Haverkamp C, Hazard D, He B, Henderson D, Hilka M, Ho Y, Holmes J, Honerlaw J, Hong C, Huling K, Hutch M, Issitt R, Jannot A, Jouhet V, Kainth M, Kate K, Kavuluru R, Keller M, Kennedy C, Kernan K, Key D, Kirchoff K, Klann J, Kohane I, Krantz I, Kraska D, Krishnamurthy A, L'Yi S, Leblanc J, Lemaitre G, Lenert L, Leprovost D, Liu M, Loh N, Long Q, Lozano-Zahonero S, Luo Y, Lynch K, Mahmood S, Maidlow S, Makoudjou A, Makwana S, Malovini A, Mandl K, Mao C, Maram A, Maripuri M, Martel P, Martins M, Marwaha J, Masino A, Mazzitelli M, Mazzotti D, Mensch A, Milano M, Minicucci M, Moal B, Ahooyi T, Moore J, Moraleda C, Morris J, Morris M, Moshal K, Mousavi S, Mowery D, Murad D, Murphy S, Naughton T, Neto C, Neuraz A, Newburger J, Ngiam K, Njoroge W, Norman J, Obeid J, Okoshi M, Olson K, Omenn G, Orlova N, Ostasiewski B, Palmer N, Paris N, Patel L, Pedrera-Jiménez M, Pfaff A, Pfaff E, Pillion D, Pizzimenti S, Priya T, Prokosch H, Prudente R, Prunotto A, Quirós-González V, Ramoni R, Raskin M, Rieg S, Roig-Domínguez G, Rojo P, Romero-Garcia N, Rubio-Mayo P, Sacchi P, Sáez C, Salamanca E, Samayamuthu M, Sanchez-Pinto L, Sandrin A, Santhanam N, Santos J, Vidorreta F, Savino M, Schriver E, Schubert P, Schuettler J, Scudeller L, Sebire N, Serrano-Balazote P, Serre P, Serret-Larmande A, Shah M, Abad Z, Silvio D, Sliz P, Son J, Sonday C, South A, Sperotto F, Spiridou A, Strasser Z, Tan A, Tan B, Tan B, Tanni S, Taylor D, Terriza-Torres A, Tibollo V, Tippmann P, Toh E, Torti C, Trecarichi E, Vallejos A, Varoquaux G, Vella M, Verdy G, Vie J, Visweswaran S, Vitacca M, Wagholikar K, Waitman L, Wang X, Wassermann D, Weber G, Wolkewitz M, Wong S, Xia Z, Xiong X, Ye Y, Yehya N, Yuan W, Zachariasse J, Zahner J, Zambelli A, Zhang H, Zöller D, Zuccaro V, Zucco C, Newburger J, Avillach P. Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium. EClinicalMedicine 2023, 64: 102212. PMID: 37745025, PMCID: PMC10511777, DOI: 10.1016/j.eclinm.2023.102212.Peer-Reviewed Original ResearchSystemic inflammatory response syndromeSARS-CoV-2 eraMultisystem inflammatory syndromeLower lymphocyte countsLower troponinInflammatory syndromeLymphocyte countRisk differenceClinical phenotypeLower C-reactive proteinSARS-CoV-2 infectionPooled risk differenceInflammatory response syndromeLength of hospitalizationObservational retrospective studyC-reactive proteinElectronic health record dataSARS-CoV-2 variantsOutcomes of MISHealth record dataEffect sizeAnticoagulation therapyClinical characteristicsRespiratory symptomsRare complicationPLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection
Xu D, Jiang W, Wu L, Gaudet R, Park E, Su M, Cheppali S, Cheemarla N, Kumar P, Uchil P, Grover J, Foxman E, Brown C, Stansfeld P, Bewersdorf J, Mothes W, Karatekin E, Wilen C, MacMicking J. PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection. Nature 2023, 619: 819-827. PMID: 37438530, PMCID: PMC10371867, DOI: 10.1038/s41586-023-06322-y.Peer-Reviewed Original ResearchConceptsC-terminal β-barrel domainSpike-mediated fusionCell-autonomous defenseLarge-scale exome sequencingΒ-barrel domainGenome-wide CRISPRSARS-CoV-2 infectionHost cell cytosolScramblase activityPhospholipid scramblaseLive SARS-CoV-2 infectionHuman lung epitheliumPLSCR1SARS-CoV-2 USASingle-molecule switchingSARS-CoV-2 variantsExome sequencingHuman populationRestriction factorsViral RNANew SARS-CoV-2 variantsSARS-CoV-2Robust activityLung epitheliumDefense factorsThe KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression
Wei J, Alfajaro M, Cai W, Graziano V, Strine M, Filler R, Biering S, Sarnik S, Patel S, Menasche B, Compton S, Konermann S, Hsu P, Orchard R, Yan Q, Wilen C. The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression. PLOS Pathogens 2023, 19: e1011351. PMID: 37410700, PMCID: PMC10325096, DOI: 10.1371/journal.ppat.1011351.Peer-Reviewed Original ResearchConceptsMouse hepatitis virusReceptor expressionTherapeutic targetMERS-CoVMajor SARS-CoV-2 variantsPrimary human airwaySARS-CoV-2 variantsNovel therapeutic targetViral receptor expressionSARS-CoV-2Histone methyltransferase KMT2DIntestinal epithelial cellsCoronavirus SusceptibilityDiverse coronavirusesHistone demethylase KDM6ADPP4 expressionCoronavirus receptorsHost determinantsHepatitis virusHuman airwaysSARS-CoVSmall molecule inhibitionViral entryPotential drug targetsViral receptorsAssociation Between SARS-CoV-2 Variants and Frequency of Acute Symptoms: Analysis of a Multi-institutional Prospective Cohort Study—December 20, 2020—June 20, 2022
Wang R, Gottlieb M, Montoy J, Rodriguez R, Yu H, Spatz E, Chandler C, Elmore J, Hannikainen P, Chang A, Hill M, Huebinger R, Idris A, Koo K, Li S, McDonald S, Nichol G, O’Laughlin K, Plumb I, Santangelo M, Saydah S, Stephens K, Venkatesh A, Weinstein R, Weinstein R, Gottlieb M, Santangelo M, Koo K, Derden A, Gottlieb M, Gatling K, Guzman D, Yang G, Kaadan M, Hassaballa M, Jerger R, Ahmed Z, Choi M, Venkatesh A, Spatz E, Lin Z, Li S, Yu H, Liu M, Venkatesh A, Spatz E, Ulrich A, Kinsman J, Dorney J, Pierce S, Puente X, Nichol G, Stephens K, Anderson J, Morse D, Adams K, Maat Z, Stober T, O’Laughlin K, Gentile N, Geyer R, Willis M, Ruiz L, Malone K, Park J, Rising K, Kean E, Kelly M, Schaeffer K, Hannikainen P, Shughart L, Shughart H, Renzi N, Amadio G, Grau D, Watts P, Cheng D, Miao J, Shutty C, Charlton A, Hill M, Site R, Chavez S, Kane A, Nikonowicz P, Idris A, McDonald S, Gallegos D, Martin R, Elmore J, Wisk L, L’Hommedieu M, Chandler C, Eguchi M, Roldan K, Villegas N, Moreno R, Rodriguez R, Wang R, Montoy J, Kemball R, Chan V, Chavez C, Wong A, Arreguin M, Plumb I, Hall A, Saydah S, Briggs-Hagen M. Association Between SARS-CoV-2 Variants and Frequency of Acute Symptoms: Analysis of a Multi-institutional Prospective Cohort Study—December 20, 2020—June 20, 2022. Open Forum Infectious Diseases 2023, 10: ofad275. PMID: 37426947, PMCID: PMC10327880, DOI: 10.1093/ofid/ofad275.Peer-Reviewed Original ResearchLoss of smellAcute symptomsSARS-CoV-2SARS-CoV-2 positive participantsFrequency of acute symptomsPrevalence of acute symptomsShortness of breathLoss of tasteChest painClinical presentationReport symptomsRespiratory virusesCohort studySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 variantsSore throatRespiratory syndrome coronavirus 2Runny noseSyndrome coronavirus 2Coronavirus disease 2019ParticipantsSymptomsCoronavirus 2Omicron
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply